Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2006

Merck Obtains Rights to Ambrilia’s HIV/AIDS Protease Inhibitor Program

  • Merck was granted worldwide rights to Ambrilia’s HIV/AIDS protease inhibitor (PI) program, according to an exclusive licensing agreement between the two companies.

    Under the terms of this agreement, Merck gained the rights to Ambrilia’s lead compound, PPL-100, which has completed a Phase I single-dose pharmacokinetic study and is currently in a Phase I repeat-dose pharmacokinetic study.

    In return, Ambrilia receives an upfront licensing fee of $17 million on signing and is eligible for cash payments totaling up to $215 million upon successful completion of development, clinical, regulatory, and sales milestones, as well as royalties on all future product sales.

    The first milestone payments of $3 million will be based on the successful completion of a Phase I repeat-dose pharmacokinetic study, the results of which are expected in late November. Once this Phase I study is completed, Merck will assume all subsequent development costs related to PPL-100.

    Ambrilia also stands to receive additional milestone-based cash payments and royalties on the future development and commercialization of each back-up compound and/or related compounds developed by Merck, which fall within the scope of the Ambrilia PI program.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »